COVID-19 Antiviral Agents and COVID-19 Rebound

In this episode, Jason Gallagher, PharmD, and Emily Heil, PharmD, MS, BCIDP discuss landmark clinical trials of COVID-19 antivirals for nonhospitalized patients and COVID-19 rebound phenomenon, including:  

• EPIC-HR study of nirmatrelvir plus ritonavir
• PINETREE study of remdesivir
• MOVe-OUT and Panoramic studies of molnupiravir
• COVID-19 rebound in treated and untreated patients

Presenters:

Jason Gallagher, PharmD
Clinical Professor
School of Pharmacy
Temple University
Clinical Pharmacy Specialist
Infectious Diseases
Temple University Hospital
Philadelphia, Pennsylvania

Emily Heil, PharmD, MS, BCIDP, AAHIVP
Associate Professor
Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Infectious Diseases Clinical Pharmacy Specialist
University of Maryland Medical Center
Baltimore, Maryland

 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.